Intrahypothalamic Mu-, not Delta- or Kappa-Opioid Receptor Activation Causes Growth Hormone Secretion

Area of Science:

• Neuroendocrinology
• Opioid receptor pharmacology

Background:

• Opioid receptors are implicated in regulating various physiological processes, including hormone secretion.
• The specific roles of different opioid receptor subtypes (mu, delta, kappa) in controlling growth hormone (GH) release remain incompletely understood.

Purpose of the Study:

• To investigate the effects of selective mu-, delta-, and kappa-opioid receptor agonists on GH secretion.
• To determine the brain regions and receptor subtypes involved in opioid-mediated GH regulation.

Main Methods:

• Localized intracerebral injections of selective opioid agonists into the preoptic anterior hypothalamic area and medial basal hypothalamus of unanaesthetized male rats.
• Serial measurement of plasma GH concentrations before and after agonist administration.
• Dose-response assessments for different opioid receptor agonists.

Main Results:

• Mu-opioid receptor agonist (DAGO) administration caused dose-responsive increases in GH secretion in both hypothalamic regions studied.
• Delta- (DPDPE) and kappa- (U50,488H) opioid receptor agonists also stimulated GH secretion, but required significantly higher doses compared to mu-agonists.
• The potency of agonists varied between the medial basal hypothalamus and the preoptic anterior hypothalamic area.

Conclusions:

• Activation of hypothalamic mu-opioid receptors plays a significant role in stimulating GH secretion.
• While other opioid receptor subtypes may influence GH release, their effects appear to be less potent or may occur at doses that also engage mu-receptors.